Anocca To Reach Clinical-Stage With T-Cell Therapies After Series B Injection
Swedish Biotech Developing Pipeline Of TCR-T Cellular Therapies
Executive Summary
Sweden-based Anocca AB will use a just completed $47m Series B financing to advance its industrialized cellular biology platform and pipeline of TCR-T cellular therapies into Phase I/IIa oncology clinical trials, its CEO tells Scrip.
You may also be interested in...
T-knife Taps Into Investor Interest in T-Cell Receptor Therapies
The German biotech has raised a significant sum to advance its T-cell therapies for solid tumors developed using its transgenic mouse technology platform.
Ipsen Buys Into BAX Inhibitor, Targeting Certain Cancers
Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.
Roche R&D Spending Surge Reflects In-House Innovation, M&A Prices
A surprise surge in Roche's R&D spending this year reflects high quality in-house innovation opportunities as well as high prices for external M&A targets, management said.